Acinar-to-Ductal Metaplasia (ADM): On the Road to Pancreatic Intraepithelial Neoplasia (PanIN) and Pancreatic Cancer

Int J Mol Sci. 2023 Jun 9;24(12):9946. doi: 10.3390/ijms24129946.

Abstract

Adult pancreatic acinar cells show high plasticity allowing them to change in their differentiation commitment. Pancreatic acinar-to-ductal metaplasia (ADM) is a cellular process in which the differentiated pancreatic acinar cells transform into duct-like cells. This process can occur as a result of cellular injury or inflammation in the pancreas. While ADM is a reversible process allowing pancreatic acinar regeneration, persistent inflammation or injury can lead to the development of pancreatic intraepithelial neoplasia (PanIN), which is a common precancerous lesion that precedes pancreatic ductal adenocarcinoma (PDAC). Several factors can contribute to the development of ADM and PanIN, including environmental factors such as obesity, chronic inflammation and genetic mutations. ADM is driven by extrinsic and intrinsic signaling. Here, we review the current knowledge on the cellular and molecular biology of ADM. Understanding the cellular and molecular mechanisms underlying ADM is critical for the development of new therapeutic strategies for pancreatitis and PDAC. Identifying the intermediate states and key molecules that regulate ADM initiation, maintenance and progression may help the development of novel preventive strategies for PDAC.

Keywords: acinar-to-ductal metaplasia (ADM); inflammation; pancreatic ductal adenocarcinoma (PDAC); pancreatic intraepithelial neoplasia (PanIN); pancreatitis; proliferation; regeneration; trans-differentiation; tumorigenesis.

Publication types

  • Review

MeSH terms

  • Acinar Cells / pathology
  • Adult
  • Carcinoma in Situ* / genetics
  • Carcinoma, Pancreatic Ductal* / genetics
  • Carcinoma, Pancreatic Ductal* / pathology
  • Humans
  • Inflammation / pathology
  • Metaplasia / pathology
  • Pancreas / pathology
  • Pancreatic Neoplasms* / genetics
  • Pancreatic Neoplasms* / pathology

Grants and funding

This research was funded by Inserm, Université Paris Cité, Gefluc-Les Entreprises Contre le Cancer, la Ligue Contre le Cancer-Comité de Paris, Fondation ARC.